Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target

MT Newswires Live

07/16

Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.

The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.

The Minder system is an implant placed under the scalp to continuously monitor brain waves.

"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting," said Epiminder CEO Rohan Hoare.

The company's shares gained over 1% in recent Thursday trade.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2651974654"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2651974654\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2651974654?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-16 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2651974654","market":"nz","top_or_hot":-1,"title":"Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target","media":"MT Newswires Live","content":"<html><body><p> Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.</p><p>The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.</p><p>The Minder system is an implant placed under the scalp to continuously monitor brain waves.</p><p>\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.</p><p>The company's shares gained over 1% in recent Thursday trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Epiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nEpiminder Reaches 50-Patient Enrollment Milestone in Epilepsy Study Ahead of Target\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-16 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.</p><p>The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.</p><p>The Minder system is an implant placed under the scalp to continuously monitor brain waves.</p><p>\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.</p><p>The company's shares gained over 1% in recent Thursday trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7007","symbol_name":"医疗保健设备","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2651974654","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2651974654","pubTimestamp":1784167702,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Epiminder  said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.The Minder system is an implant placed under the scalp to continuously monitor brain waves.\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.The company's shares gained over 1% in recent Thursday trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7007":"医疗保健设备","EPI.AU":"Epiminder Limited"},"translate_title":"Epiminder 在癫痫研究中提前达到 50 名患者入组里程碑","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EPI.AU":1},"content_text":"Epiminder (ASX:EPI) said it has now enrolled 50 patients in a US clinical study evaluating the Minder system as a tool to improve clinical decision-making for patients with epilepsy, according to a Thursday filing with the Australian bourse.The company hit the enrollment milestone in the Detect study ahead of its mid-third quarter target, and remains on track to enroll 210 patients by the end of the first half of 2027, per the filing.The Minder system is an implant placed under the scalp to continuously monitor brain waves.\"With 20 leading epilepsy centers now actively enrolling, we are seeing genuine, demonstrated adoption of the Minder System in a clinical setting,\" said Epiminder CEO Rohan Hoare.The company's shares gained over 1% in recent Thursday trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}